Med SciforuMed Sciforu

Interface in English. Medical references retain their original language; bilingual names and selected translations are provided.

西药 · 美国药品标签原文

Alcaine

PROPARACAINE HYDROCHLORIDE

Alcaine · Alcon Laboratories, Inc.。此记录对应特定产品,标签收录不代表所有用途获批。

说明与适用边界

此页按所列地区、版本归档。标签内容可能更新,具体产品请核对原始来源;本站关联表示阅读线索,不表示药品与器械可兼容或可替换。

spl product data elements

Alcaine proparacaine hydrochloride PROPARACAINE HYDROCHLORIDE PROPARACAINE BENZALKONIUM CHLORIDE GLYCERIN WATER HYDROCHLORIC ACID SODIUM HYDROXIDE Carton Label Container Label

描述 / Description

DESCRIPTION: ALCAINE™ (proparacaine hydrochloride ophthalmic solution, USP) 0.5% is a topical local anesthetic for ophthalmic use. The active ingredient is represented by the structural formula: Established Name: Proparacaine Hydrochloride Chemical Name: Benzoic acid, 3-amino-4-propoxy-,2-(diethylamino) ethyl ester, monohydrochloride. Molecular Weight: 330.85 g/mol Each mL contains of ALCAINE™ (proparacaine hydrochloride ophthalmic solution, USP) 0.5%: Active: proparacaine hydrochloride 5 mg 0.5%. Preservative: benzalkonium chloride (0.01%). Inactives: glycerin and purified water. The pH may be adjusted with hydrochloric acid and/or sodium hydroxide. chemical

临床药理 / Clinical pharmacology

CLINICAL PHARMACOLOGY: ALCAINE™ ophthalmic solution is a rapidly-acting topical anesthetic, with induced anesthesia lasting approximately 10-20 minutes.

适应证 / Indications and usage

INDICATIONS AND USAGE: ALCAINE™ ophthalmic solution is indicated for procedures in which a topical ophthalmic anesthetic is indicated: corneal anesthesia of short duration, e.g. tonometry, gonioscopy, removal of corneal foreign bodies, and for short corneal and conjunctival procedures.

禁忌 / Contraindications

CONTRAINDICATIONS: ALCAINE™ ophthalmic solution should be considered contraindicated in patients with known hypersensitivity to any of the ingredients of this preparation.

警告 / Warnings

WARNINGS: NOT FOR INJECTION - FOR TOPICAL OPHTHALMIC USE ONLY. Prolonged use of a topical ocular anesthetic is not recommended. It may produce permanent corneal opacification with accompanying visual loss. ALCAINE™ ophthalmic solution is indicated for administration under the direct supervision of a healthcare provider. ALCAINE™ ophthalmic solution is not intended for patient self-administration.

注意事项 / Precautions

PRECAUTIONS: Carcinogenesis, Mutagenesis, Impairment of Fertility. Long-term studies in animals have not been performed to evaluate carcinogenic potential, mutagenicity, or possible impairment of fertility in males or females. Pregnancy: Animal reproduction studies have not been conducted with ALCAINE ™ (proparacaine hydrochloride ophthalmic solution, USP) 0.5%. It is also not known whether proparacaine hydrochloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Proparacaine hydrochloride should be administered to a pregnant woman only if clearly needed.

carcinogenesis and mutagenesis and impairment of fertility

Carcinogenesis, Mutagenesis, Impairment of Fertility. Long-term studies in animals have not been performed to evaluate carcinogenic potential, mutagenicity, or possible impairment of fertility in males or females.

妊娠 / Pregnancy

Pregnancy: Animal reproduction studies have not been conducted with ALCAINE ™ (proparacaine hydrochloride ophthalmic solution, USP) 0.5%. It is also not known whether proparacaine hydrochloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Proparacaine hydrochloride should be administered to a pregnant woman only if clearly needed.

哺乳 / Nursing mothers

Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when proparacaine hydrochloride is administered to a nursing woman.

儿科 / Pediatric use

Pediatric Use: Safety and effectiveness of proparacaine hydrochloride ophthalmic solution in pediatric patients have been established. Use of proparacaine hydrochloride is supported by evidence from adequate and well-controlled studies in adults and children over the age of twelve, and safety information in neonates and other pediatric patients.

老年人 / Geriatric use

Geriatric Use: No overall clinical differences in safety or effectiveness have been observed between the elderly and other adult patients.

不良反应 / Adverse reactions

ADVERSE REACTIONS: Occasional temporary stinging, burning and conjunctival redness may occur with the use of proparacaine. Corneal edema has been reported following the use of proparacaine. A rare, severe, immediate-type, apparently hyperallergic corneal reaction characterized by acute, intense and diffuse epithelial keratitis, a gray, ground glass appearance, sloughing of large areas of necrotic epithelium, corneal filaments and, sometimes, iritis with descemetitis has been reported. Allergic contact dermatitis from proparacaine with drying and fissuring of the fingertips has also been reported.

用法用量原文 / Dosage and administration

DOSAGE AND ADMINISTRATION: Usual Dosage: Removal of foreign bodies and sutures, and for tonometry: 1 to 2 drops (in single instillations) in each eye before operating. Short Corneal and Conjunctival Procedures: 1 drop in each eye every 5 to 10 minutes for 5 to 7 doses. NOTE: ALCAINE™ (proparacaine hydrochloride ophthalmic solution, USP) 0.5% should be clear to straw-color. If the solution becomes darker, discard the solution.

包装供应 / How supplied

HOW SUPPLIED: ALCAINE™ (proparacaine hydrochloride ophthalmic solution, USP) 0.5% is supplied in DROP-TAINER® dispensers as follows: 15 mL NDC 0998-0016-15 Storage: Bottle must be stored in unit carton to protect contents from light. Store bottles under refrigeration at 2°C to 8°C (36°F to 46°F). After opening, ALCAINE™ can be used until the expiration date on the bottle. NOTE: ALCAINE™ (proparacaine hydrochloride ophthalmic solution, USP) 0.5% should be clear to straw-color. If the solution becomes darker, discard the solution. Distributed by: ALCON LABORATORIES, INC. Fort Worth, Texas 76134 Revised: 06/2024 Alcon Alcon Laboratories, Inc. 6201 South Freeway Fort Worth, Texas 76134 USA © 2024 Alcon Inc. Printed in USA [email protected] 1-800-757-9195 300063110-0723

package label principal display panel

PRINCIPAL DISPLAY PANEL NDC 0998-0016-15 Alcon Alcaine ™ (proparacaine hydrochloride ophthalmic solution USP) 0.5% 15 mL Sterile Rx Only PRECAUTION: NOT FOR INJECTION. FOR TOPICAL OPHTHALMIC USE ONLY. Do not touch dropper tip to any surface, as this may contaminate the solution. USUAL DOSAGE: 1 or 2 drops. Read enclosed insert. Bottles must be stored in unit carton to protect from light. STORAGE: Store between 2º to 8ºC (36º to 46ºF). After opening, ALCAINE™ can be used until the expiration date on the bottle. ALCAINE ™ (proparacaine hydrochloride ophthalmic solution) should be clear to straw-color. If the solution becomes darker, discard the solution. INGREDIENTS: Each mL contains: Active: proparacaine hydrochloride 5 mg (0.5%). Preservative: benzalkonium chloride 0.01%. Inactives : glycerin, hydrochloric acid and/or sodium hydroxide (to adjust pH), purified water pH range 4.0 to 6.0 1-800-757-9195 [email protected] Country of Origin: Switzerland Alcon ALCON LABORATORIES, INC. 6201 South Freeway Fort Worth, Texas 76134 USA Printed in USA 300056033-0922 NDC 0998-0016-15 Alcon Alcaine ™ (proparacaine hydrochloride ophthalmic solution USP) 0.5% Sterile 15 mL Rx Only PRECAUTION: NOT FOR INJECTION. FOR TOPICAL OPHTHALMIC USE ONLY. Do not touch dropper tip to any surface as this may contaminate the solution. USUAL DOSAGE: 1 or 2 drops. Read enclosed insert. STORAGE: Store between 2º to 8ºC (36º to 46ºF). After opening, ALCAINE ™ can be used until the expiration date on the bottle. Bottles must be stored in unit carton to protect from light. ALCAINE ™ (proparacaine hydrochloride ophthalmic solution) should be clear to straw-color. If the solution becomes darker, discard the solution. INGREDIENTS: Each mL contains: Active: proparacaine hydrochloride 5 mg (0.5%). ALCON LABORATORIES, INC. Fort Worth, Texas 76134 USA Printed in USA LOT/EXP.:

来源、版本与许可

资料类型
美国药品标签原文
版本
12 / 20260610
获取时间
2026-10-08
许可
openFDA public data; retain original label attribution. See 查看来源 and dataset source notices. Public access does not imply approval or unrestricted rights to every submitted label.
核对原始来源